Cigna Corporation

🇺🇸New York Stock Exchange
Back to all articles
Cigna Corporation stock analysis CI overview
Bullish +65

Folger Nolan Fleming Douglas Capital Management Inc. Purchases New ...

📈 Folger Nolan Fleming Douglas Capital Management Inc. acquired a new position in Cigna Group consisting of 3,521 shares valued at approximately $939,000 during the first quarter.

📊 Institutional ownership remains high at 86.99%, with significant increases from Brighton Jones LLC (+9.3%), Sivia Capital Partners (+10.4%), NewEdge Advisors (+4.5%), and the Treasurer of the State of North Carolina (+16.6%).

🏦 UBS Group raised its price target on Cigna Group from $375.00 to $400.00 and maintained a 'buy' rating in a research note dated May 22nd.

📉 Royal Bank Of Canada increased its price target to $337.00 with an 'outperform' rating, while Guggenheim raised its objective to $338.00 with a 'buy' rating.

💰 Cigna Group reported quarterly EPS of $7.79, beating analyst estimates of $7.60, and revenue of $68.52 billion, surpassing the expected $66.29 billion.

📈 Revenue for the quarter increased by 4.6% compared to the same period last year, demonstrating consistent growth in the health services sector.

🎯 The company set full-year 2026 EPS guidance between $30.35 and $30.39, which aligns closely with analyst forecasts of $30.39.

💵 Cigna Group declared a quarterly dividend of $1.56 per share, resulting in an annualized dividend yield of 2.2% for stockholders of record on June 4th.

📉 CEO David Cordani sold 201,878 shares valued at approximately $59.1 million under a pre-arranged Rule 10b5-1 trading plan on May 12th.

📉 CAO Jamie G. Kates sold 899 shares valued at approximately $268,450 on June 12th, reducing his personal ownership by 27.52%.

📊 The stock currently trades with a market capitalization of $73.90 billion and a P/E ratio of 11.84, trading above its 200-day moving average of $278.96.

🏥 Cigna Group operates as a global health services company offering medical plans, dental/vision coverage, pharmacy benefit management, and supplemental health products.

Bullish Signals
  • Cigna Group beat quarterly earnings estimates with EPS of $7.79 versus the consensus of $7.60, indicating strong operational performance.
  • Revenue for the quarter reached $68.52 billion, exceeding analyst expectations of $66.29 billion and growing 4.6% year-over-year.
  • UBS Group raised its price target significantly from $375.00 to $400.00 while maintaining a 'buy' rating, signaling strong institutional confidence.
  • Multiple major brokerages including Royal Bank Of Canada, Robert W. Baird, and Guggenheim issued 'buy' or 'outperform' ratings with price targets above current levels.
  • The company's full-year 2026 EPS guidance of $30.35-$30.39 aligns closely with analyst forecasts of $30.39, suggesting accurate management forecasting.
  • Cigna Group maintains a healthy dividend yield of 2.2% with an annualized payout of $6.24 per share and a sustainable payout ratio of 26.45%.
Risk Factors
  • CEO David Cordani executed a significant sale of 201,878 shares worth approximately $59.1 million, reducing his personal ownership by 85.46%.
  • CAO Jamie G. Kates sold 899 shares valued at approximately $268,450, representing a 27.52% decrease in his personal stock holdings.
Full Analysis
Folger Nolan Fleming Douglas Capital Management Inc. acquired a new position in Cigna Group (NYSE:CI) during the first quarter, purchasing 3,521 shares valued at approximately $939,000. Other institutional investors also adjusted their stakes, with Brighton Jones LLC increasing its position by 9.3% to own 3,736 shares and Sivia Capital Partners raising its stake by 10.4%. NewEdge Advisors and the Treasurer of the State of North Carolina also boosted their holdings, while Osterweis Capital Management initiated a new position valued at $163,000. Several major brokerages have recently issued positive research reports on Cigna Group. Royal Bank Of Canada raised its price target to $337.00 with an 'outperform' rating, while Robert W. Baird and Guggenheim set price objectives at $337.00 and $338.00 respectively, both with 'buy' ratings. UBS Group significantly increased its target from $375.00 to $400.00, maintaining a 'buy' rating, and Wells Fargo raised its target to $305.00. The consensus average price target stands at $338.30 with an overall 'Moderate Buy' rating. Cigna Group reported strong quarterly earnings on April 30th, beating analyst estimates with EPS of $7.79 against a consensus of $7.60 and revenue of $68.52 billion versus an expected $66.29 billion. The company's revenue grew 4.6% year-over-year, and it has set full-year 2026 guidance for EPS between $30.35 and $30.39, which aligns closely with analyst forecasts of $30.39. Additionally, the firm declared a quarterly dividend of $1.56 per share, paid on June 18th to stockholders of record on June 4th.